Hepatitis C testing
Proportion of people starting antiretroviral therapy who were tested for hepatitis C virus (HCV)
What it measures
It monitors trends in hepatitis C testing, a critical intervention for assessing needs related to managing hepatitis C.
Hepatitis C testing provides information on the prevalence of HIV and HCV coinfection, informing clinicians on the need for further clinical and laboratory evaluation and treatment.
Testing for hepatitis C identifies HIV and HCV coinfection to adapt treatment
Number of adults and children starting antiretroviral therapy who were tested for hepatitis C during the reporting period using the sequence of anti-HCV antibody tests followed by HCV polymerase chain reaction (PCR) for those who are anti-HCV positive.
Number of adults and children starting antiretroviral therapy during the reporting period
Method of measurement
Clinical and/or laboratory records
- Age (<15 and 15+ years)
- People who inject drugs
Strengths and weaknesses
Patients who are anti-HCV positive have serological evidence of past or present infection. People who are anti-HCV positive must be tested for HCV RNA (detects HCV circulating in the blood) to differentiate resolved infections from current infections that require treatment.
This indicator monitors progress in hepatitis C testing activities on a regular basis but does not reflect the overall proportion of people coinfected HIV and HCV receiving HIV care who are aware of their hepatitis C coinfection. Indicator C.6 of the viral hepatitis monitoring and evaluation framework, disaggregated by HIV status, would reflect this.
This indicator corresponds to indicator LINK.28 (Rev.1) of the 2015 WHO consolidated strategic information guidelines for HIV in the health sector. The revision comprised considering people starting antiretroviral therapy, since this is the best moment to test people living with HIV for coinfection to initiate treatment.